Integra LifeSciences Holding Corp. (IART) announced on Wednesday April 26, 2017 that sales for the first quarter of 2017 rose 9.2% (excluding currency and acquisitions). Sales for the quarter were $258.6 million, which is up from $236.7 million reported in the first quarter of 2016.
IART Posts 9.21% First Quarter Sales Increase
1 min read Premium comments
Secondary
IART, which is headquartered in Plainsboro, New Jersey, is a surgical and medical instrument manufacturing company. The following table shows the sales details for 2017.
" data-large-file="https://i0.wp.com/ryortho.com/wp-content/uploads/2017/05/Integra_1Q17Table.jpg?fit=730%2C129&ssl=1" src="https://i0.wp.com/ryortho.com/wp-content/uploads/2017/05/Integra_1Q17Table.jpg?resize=730%2C129&ssl=1" alt="" width="730" height="129">Source: Integra LifeSciences Holdings Corp. company documents
Glenn Novarro, an analyst with RBC Capital Markets, LLC, said in his report, “Overall IART reported solid [first quarter 2017] results and reiterated its full-year 2017 revenue and EPS guidance.”
He added, “Both global segments contributed to the growth with revenue in Orthopedics and Tissue Technologies and Specialty Surgical Solutions increasing by 19.6% and 3.4%, respectively, compared to the prior year.”
Peter Arduini, company president and chief executive officer in a release said, “We are off to a solid start in 2017, which gives us increased confidence in delivering on our full-year 2017 financial guidance.”
Arduini added, “We completed the acquisition of Derma Sciences, launched several new products that will drive growth in the second half of the year, and remain on track to complete the planned acquisition of Codman Neurosurgery in the fourth quarter of 2017.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.